Clinical trials: ALS
Amyotrophic Lateral Sclerosis
Efficacy and Safety of Plasma Exchange With Albutein® 5% in Participants With Amyotrophic Lateral Sclerosis
This is a pilot, phase 2, prospective, open-label, single-arm study to evaluate disease progression, forced vital capacity, and the safety and tolerability of plasma exchange (PE) using Albutein® 5% in participants with…
- Trial name
- NCT02872142
- Testing
- Albutein 5%, Plasma Exchange
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Grifols Therapeutics LLC
Amyotrophic Lateral Sclerosis
RT001 in Amyotrophic Lateral Sclerosis
RT001-014 is a Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects with Amyotrophic Lateral Sclerosis
- Trial name
- NCT04762589
- Testing
- RT001
- Where
- 4 sites in Estonia, Latvia and 2 more
- Volunteers
- 43 people
- Sponsor
- Biojiva LLC
Amyotrophic Lateral Sclerosis
A 12-week, Multicenter, Safety and Dose-ranging Study of 3 Oral Doses of TCH346 in Patients With Amyotrophic Lateral Sclerosis
This study is the first to be performed in Amyotrophic Lateral Sclerosis (ALS) patients with the novel compound TCH346. Its purpose is to evaluate the safety and clinical effects of 3 dose levels of TCH 346 compared to placebo in…
- Trial name
- NCT00036413
- Testing
- TCH346
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Novartis Pharmaceuticals
Amyotrophic Lateral Sclerosis, Frontotemporal Dementia
Open-label Extension (OLE) Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD)
This is an OLE study conducted to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and clinical effects of WVE-004 in adult participants with ALS, FTD, or mixed ALS/FTD phenotype with a documented…
- Trial name
- NCT05683860
- Testing
- WVE-004 10 mg Q12W
- Where
- 3 sites in Netherlands, United Kingdom
- Volunteers
- 8 people
- Sponsor
- Wave Life Sciences USA, Inc.
Amyotrophic Lateral Sclerosis
Safety and Biomarker Study of EPI-589 in Participants With Amyotrophic Lateral Sclerosis (ALS)
This is an open label study with 30-day run in phase to establish baseline parameters, 90-day treatment phase, and a 90-day withdrawal phase to determine long-term effects, duration of treatment response, and potential effects of…
- Trial name
- EPI-589 (NCT02460679)
- Testing
- EPI-589
- Where
- 3 sites in United States
- Volunteers
- 19 people
- Sponsor
- PTC Therapeutics
Amyotrophic Lateral Sclerosis
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adults With Amyotrophic Lateral Sclerosis
The primary objective of this study is to evaluate the safety, tolerability of single-ascending doses of BIIB100 in adults with amyotrophic lateral sclerosis (ALS).
- Trial name
- NCT03945279
- Testing
- BIIB100
- Where
- 9 sites in United States
- Volunteers
- 49 people
- Sponsor
- Biogen
ALS (Amyotrophic Lateral Sclerosis), ALS
Kamlanoflast In Amyotrophic Lateral Sclerosis
This is a study of Kamlanoflast in patients with ALS. Kamlanoflast is orally administered over 24 weeks. Its effects on inflammatory and functional parameters will be studied.
- Conditions
- ALS (Amyotrophic Lateral Sclerosis), ALS, Neuro-Degenerative Disease, Neuro-Degenerative Diseases
- Trial name
- NCT07396818
- Testing
- Kamlanoflast
- Volunteers
- 40 people
- Sponsor
- Inflammasome Therapeutics
Amyotrophic Lateral Sclerosis
Brain-Computer Interface Communication Device for People With ALS
This study compares a wearable brain-computer interface (BCI) communication device with the eye-tracking communication devices that people with ALS already use.
- Trial name
- NCT07871071
- Testing
- Cognixion ONE AR-BCI configuration, Cognixion ONE screen-based BCI configuration, Existing eye-gaze speech generating device
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Cognixion
Amyotrophic Lateral Sclerosis
Study Evaluating TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis (ALS)
This is a global multicenter study designed to evaluate the safety and clinical effects of 4 oral doses of TCH346 (1.0, 2.5, 7.5, and 15 mg) compared to placebo in patients with mild or mild to moderate stages of ALS.
- Trial name
- NCT00072709
- Testing
- TCH346
- Where
- 9 sites in United States, Belgium and 7 more
- Volunteers
- 551 people
- Sponsor
- Novartis Pharmaceuticals
Amyotrophic Lateral Sclerosis
A Study to Explore the Safety and Tolerability of Acthar in Patients With Amyotrophic Lateral Sclerosis
This 8-week randomized, open-label evaluation will examine the acute safety and tolerability of 4 different dosing regimens of Acthar to inform dose selection for future studies of Acthar in patients with Amyotrophic Lateral…
- Trial name
- NCT01906658
- Testing
- Repository corticotropin injection
- Where
- 17 sites in United States
- Volunteers
- 43 people
- Sponsor
- Mallinckrodt
Amyotrophic Lateral Sclerosis, Lou Gehrig Disease
MRG-001 in Patients With Amyotrophic Lateral Sclerosis
The proposed study is an Open-Label, Single-Dose Study to Assess the Safety, and Pharmacodynamics (PD) signals of MRG-001 in Patients with Amyotrophic Lateral Sclerosis (ALS).
- Conditions
- Amyotrophic Lateral Sclerosis, Lou Gehrig Disease, Motor Neuron Disease, Motor Neuron Atrophy
- Trial name
- NCT06315608
- Testing
- MRG-001
- Volunteers
- 10 people
- Sponsor
- MedRegen LLC
Amyotrophic Lateral Sclerosis, Renal Insufficiency
Dexpramipexole Renal PK Study
This is a multicenter, open-label, single-dose, PK and safety study in subjects with various stages of renal impairment.
- Trial name
- NCT01424176
- Testing
- Dexpramipexole (dose 1), Dexpramipexole (dose 2)
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Knopp Biosciences
Tetraplegia/Tetraparesis, Quadriplegia
Precise Robotically IMplanted Brain-Computer InterfacE
The PRIME Study is a first-in-human early feasibility study to evaluate the initial clinical safety and device functionality of the Neuralink N1 Implant and R1 Robot device designs in participants with tetraparesis or…
- Conditions
- Tetraplegia/Tetraparesis, Quadriplegia, Cervical Spinal Cord Injury, Amyotrophic Lateral Sclerosis
- Trial name
- PRIME (NCT06429735)
- Testing
- N1 Implant, R1 Robot
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Neuralink Corp
Amyotrophic Lateral Sclerosis
Safety Extension Study of TRO19622 in ALS
The purpose of the assay is to assess the safety of TRO19622 330 mg QD as add-on therapy to riluzole 50 mg bid in the treatment of patients suffering from ALS, after completion of the preceding clinical trial (TRO19622 CL E Q…
- Trial name
- NCT01285583
- Testing
- TRO19622
- Where
- 15 sites in Belgium, France and 3 more
- Volunteers
- 271 people
- Sponsor
- Hoffmann-La Roche
Amyotrophic Lateral Sclerosis
A Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL343 in Participants With Amyotrophic Lateral Sclerosis
This is a Phase 1b, multicenter, randomized, placebo-controlled, double-blind study of 28 days, followed by an 18-month open-label extension, designed to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of…
- Trial name
- NCT05006352
- Testing
- DNL343
- Where
- 7 sites in United States, Netherlands
- Volunteers
- 29 people
- Sponsor
- Denali Therapeutics Inc.
Amyotrophic Lateral Sclerosis
Exploratory Study of Biotelemetry in Amyotrophic Lateral Sclerosis
Study 201283 is an exploratory, non-controlled, non-drug study in Amyotrophic Lateral Sclerosis (ALS) subjects. This study is being conducted as the first step for developing new meaningful measure(s) which might prove to be more…
- Trial name
- NCT02447952
- Testing
- Faros Sensor (FS) and LifeInsight Hub, Fast Fix electrode patch, Quantitative Measure of Speech (Core Phase Only)
- Where
- 2 sites in United Kingdom
- Volunteers
- 25 people
- Sponsor
- GlaxoSmithKline
Amyotrophic Lateral Sclerosis
Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS
PIONEER-ALS is a Phase 1/2, multicenter, open-label, ascending dose, uncontrolled, first-in-human study that will evaluate the safety, tolerability and effects on clinical and biomarker endpoints of intracisternal administration…
- Trial name
- ALS (NCT07287397)
- Testing
- VTx-002, Preventative (Prophylactic) Medication - Corticosteroids: Methylprednisolone
- Where
- 11 sites in United States, Belgium and 2 more
- Volunteers
- 36 people
- Sponsor
- Vector Y Therapeutics
Amyotrophic Lateral Sclerosis, Cytochrome P-450 Enzyme System
A Study of LY3873862 in Participants With Sporadic or Familial Amyotrophic Lateral Sclerosis (ALS).
The main purpose of this study in participants with Sporadic or Familial Amyotrophic Lateral Sclerosis (ALS) is to test the safety of different doses and to determine the amount of LY3873862 that gets into the bloodstream and how…
- Trial name
- NCT07883590
- Testing
- LY3873862, CYP450 Drug Cocktail
- Where
- 4 sites in United States, Canada
- Volunteers
- 32 people
- Sponsor
- Eli Lilly and Company
ALS, Amyotrophic Lateral Sclerosis
Intermediate Expanded Access Protocol CNMAu8.EAP04
An Intermediate Expanded Access Protocol (EAP) with CNM-Au8 for Amyotrophic Lateral Sclerosis for NIH Grant RFA-NS-23-012
- Conditions
- ALS, Amyotrophic Lateral Sclerosis, PALS
- Trial name
- NCT06408727
- Testing
- CNM-Au8
- Where
- 8 sites in United States
- Sponsor
- Clene Nanomedicine
Pulmonary Disease, Chronic Obstructive, Amyotrophic Lateral Sclerosis
European Home Mechanical Ventilation Registry
The European Home Mechanical Ventilation Registry (EHMVR) will enable a thorough evaluation of HMV by documenting the characteristics of HMV patients and their treatment.
- Conditions
- Pulmonary Disease, Chronic Obstructive, Amyotrophic Lateral Sclerosis, Spinal Cord Injury, Muscular Dystrophies
- Trial name
- EHMVR (NCT02315339)
- Where
- Germany
- Volunteers
- 37 people
- Sponsor
- ResMed